[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020011535A - Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. - Google Patents

Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.

Info

Publication number
MX2020011535A
MX2020011535A MX2020011535A MX2020011535A MX2020011535A MX 2020011535 A MX2020011535 A MX 2020011535A MX 2020011535 A MX2020011535 A MX 2020011535A MX 2020011535 A MX2020011535 A MX 2020011535A MX 2020011535 A MX2020011535 A MX 2020011535A
Authority
MX
Mexico
Prior art keywords
retina
medicament
eye drop
sustained delivery
drop formulation
Prior art date
Application number
MX2020011535A
Other languages
English (en)
Inventor
Glenn T Huang
Vernon G Wong
Original Assignee
Chibi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chibi Inc filed Critical Chibi Inc
Publication of MX2020011535A publication Critical patent/MX2020011535A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las modalidades de la presente proporcionan composiciones, métodos y equipos para el tratamiento de condiciones o males oculares que afectan la parte posterior del ojo, por ejemplo, la retina.
MX2020011535A 2018-05-01 2019-05-01 Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. MX2020011535A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862665273P 2018-05-01 2018-05-01
PCT/US2019/030290 WO2019213326A1 (en) 2018-05-01 2019-05-01 Eye drop formulation and method for sustained delivery of medicament to the retina

Publications (1)

Publication Number Publication Date
MX2020011535A true MX2020011535A (es) 2020-11-24

Family

ID=68386777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011535A MX2020011535A (es) 2018-05-01 2019-05-01 Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.

Country Status (9)

Country Link
US (1) US11497710B2 (es)
EP (1) EP3787609A4 (es)
JP (1) JP2021523222A (es)
CN (1) CN112423740A (es)
AU (1) AU2019262061A1 (es)
BR (1) BR112020022083A2 (es)
CA (1) CA3097926A1 (es)
MX (1) MX2020011535A (es)
WO (1) WO2019213326A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202010742UA (en) * 2018-05-01 2020-11-27 Chibi Inc Liquid depot for non-invasive sustained delivery of agents to the eye

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10030378A1 (de) * 2000-06-21 2002-03-14 Audit Inst For Medical Service Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
NZ551990A (en) * 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US7906136B2 (en) * 2004-10-01 2011-03-15 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
SG185955A1 (en) * 2007-11-05 2012-12-28 Bausch & Lomb Water-immiscible materials as vehicles for drug delivery
CN102238949A (zh) 2008-10-09 2011-11-09 拉姆斯科股份有限公司 治疗干眼综合征的组合物和方法
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
LT2717914T (lt) 2011-06-10 2020-03-25 Ramscor, Inc. Sulėtinto atpalaidavimo kompozicijos, skirtos baltymų pateikimui į akį, ir jų paruošimo būdai
US9289428B2 (en) * 2011-06-10 2016-03-22 Ramscor, Inc. Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer
KR101979051B1 (ko) * 2011-12-05 2019-05-15 카무러스 에이비 강력한 방출-조절된 제형
EP3096617A4 (en) * 2014-01-23 2017-09-13 Akebia Therapeutics Inc. Compositions and methods for treating ocular diseases
CN114191420A (zh) 2014-05-29 2022-03-18 雷迪厄斯制药公司 稳定的大麻素类化合物制剂
CA2979971A1 (en) * 2015-03-18 2016-09-22 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
CN204581946U (zh) * 2015-04-25 2015-08-26 刘勇 一种眼药水存放装置
US10668011B2 (en) * 2016-06-30 2020-06-02 Durect Corporation Depot formulations
SG11202010742UA (en) 2018-05-01 2020-11-27 Chibi Inc Liquid depot for non-invasive sustained delivery of agents to the eye

Also Published As

Publication number Publication date
CN112423740A (zh) 2021-02-26
US20200368153A1 (en) 2020-11-26
AU2019262061A1 (en) 2020-11-26
US11497710B2 (en) 2022-11-15
BR112020022083A2 (pt) 2021-02-02
CA3097926A1 (en) 2019-11-07
JP2021523222A (ja) 2021-09-02
EP3787609A1 (en) 2021-03-10
WO2019213326A1 (en) 2019-11-07
EP3787609A4 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
PH12020551766A1 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
MX2020003534A (es) Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
EP4397375A3 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
SG11202008901WA (en) Ophthalmic compositions, and ocular uses thereof, of indigo carmine
MX2021013447A (es) Composiciones y procedimientos para el tratamiento de enfermedades oculares.
CL2019002839A1 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
PH12021550372A1 (en) The use of alpha-2-adrenergic receptor agonists for improving vision
JOP20200253A1 (ar) تركيبات وطرق لعلاج الحثل البقعي
MY178169A (en) Topical ophthalmic peptide formulation
TN2019000112A1 (en) Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma
MX2020011536A (es) Deposito de liquido para liberacion sostenida no invasiva de agentes al ojo.
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2020011535A (es) Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina.
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
MX2022010317A (es) Composiciones farmaceuticas de agonistas de receptores alpha-2-adrenergicos y su uso para mejorar la vision.